Sector Chart BioCryst Pharmaceuticals, Inc.
Stocks
BCRX
US09058V1035
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
23:00:00 08/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 9.065 USD | -8.99% |
|
-8.62% | +16.22% |
| 09-08 | Pharvaris' genetic disorder drug meets main goal in late-stage trial | RE |
| 08-25 | BioCryst Pharmaceuticals Announces Approval Of ORLADEYO For Pediatric HAE Patients In Japan | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 2.32B | - | - | - | ||
| 69.19B | |||||
| 62.97B | |||||
| 27.27B | - | ||||
| 24.78B | - | ||||
| 25.8B |
Select your edition
All financial news and data tailored to specific country editions
